BioPharma-Synergy (23rd -25th February 2021)
The event is designed for the BD&Licensing pharma professionals focusing on BioSimilars, BioBetter & BioInnovative products. With the audience coming from Europe, LATAM, APAC, MENA & North America – BioPharma-Synergy invites dynamic pharma companies for three days of business partnering meetings and content-driven programme.
Discussions and presentations
The 2021 content-driven programme will focus on successful commercial strategies, pricing consideration, facilitating partnering across Geos between producers and buyers. Among the topics:
Global Biosimilars/Biobetter outlook; key players and their market access strategies
Regulatory approvals, tenders and pricing trends in Europe
Opportunities and trends in biosimilars by region: APAC, MENA, CIS, LATAM
Strategic considerations for biosimilar commercialisation – manufacturers’ point of view
In-licensing strategies in Europe and beyond
Early speaker confirmations include:
o Jamie Unwin, VP & Head, Global Business Intelligence & Analytics, Biocon Biologics
o Jean-Baptiste Duval, Head of International Operations Shanghai Henlius Biotech
o Jayapala Reddy, Associate Vice-President/Global Head, Hetero Biopharma
o Philippe Gautron, Senior Director of Global Business Development own brands, DKSH
o Eduardo Cioppi, Regional Director – Latin America, mAbxience
o Stephani Saverio, Senior Director of Business Development, Knight Therapeutics
o Xiaoli Hu, Head of Business Development, Xbrane Biopharma AB
o Pavan Handa, Executive Vice President and Chief Business Officer, Kashiv Pharm
o Thiago Mares Guia, Scientific & Business Executive Director, Bionovis
o Carlos Berrade, Licensing & Business Development Director, Strategy and Development Area, Kern Pharma